Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells

Cancer Letters

Volumn 287, Issue 2, 2010, Pages 207-215

  Palacios, Carmen ^a   López Pérez, Ana Isabel ^a   López Rivas, Abelardo ^a  

^a CSIC   (Spain)

Author keywords

17DMAG; Apoptosis; RIP1; TRAIL

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; BINDING PROTEIN; CASPASE 8; CASPASE 9; HEAT SHOCK PROTEIN 90 INHIBITOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECEPTOR INTERACTING PROTEIN 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; I-KAPPA B PROTEINS; LACTAMS, MACROCYCLIC; MITOCHONDRIA; PHOSPHORYLATION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 72949090340     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.012     Document Type: Article

References (42)

1. Pearl L.H., Prodromou C., and Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 410 (2008) 439-453
2. Panaretou B., Prodromou C., Roe S.M., et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17 (1998) 4829-4836
3. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8 (2002) S55-61
4. Hollingshead M., Alley M., Burger A.M., et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride) a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 56 (2005) 115-125
5. Hwang K., Scripture C.D., Gutierrez M., Kummar S., Figg W.D., and Sparreboom A. Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830 (2006) 35-40
6. Sprick M.R., Weigand M.A., Rieser E., et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000) 599-609
7. Varfolomeev E., Maecker H., Sharp D., et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280 (2005) 40599-40608
8. Song J.H., Tse M.C., Bellail A., et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 67 (2007) 6946-6955
9. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
10. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
11. Ma Y., Lakshmikanthan V., Lewis R.W., and Kumar M.V. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol. Cancer Ther. 5 (2006) 170-178
12. Siegelin M.D., Habel A., and Gaiser T. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol. Dis. 33 (2009) 243-249
13. Vasilevskaya I.A., and O'Dwyer P.J. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem. Pharmacol. 70 (2005) 580-589
14. Wang X., Ju W., Renouard J., Aden J., Belinsky S.A., and Lin Y. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res. 66 (2006) 1089-1095
15. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., and Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59 (1999) 734-741
16. Ruiz-Ruiz C., and Lopez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem. J. 365 (2002) 825-832
17. MacFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., and Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272 (1997) 25417-25420
18. Palacios C., Yerbes R., and Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res. 66 (2006) 8858-8869
19. Herrero-Martin G., Hoyer-Hansen M., Garcia-Garcia C., et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28 (2009) 677-685
20. Bodmer J.L., Holler N., Reynard S., et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2 (2000) 241-243
21. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
22. Desagher S., Osen-Sand A., Nichols A., et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. 144 (1999) 891-901
23. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
24. Dogan T., Harms G.S., Hekman M., et al. X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat. Cell Biol. 10 (2008) 1447-1455
25. Fortugno P., Beltrami E., Plescia J., et al. Regulation of survivin function by Hsp90. P. Natl. Acad. Sci. USA 100 (2003) 13791-13796
26. Kelliher M.A., Grimm S., Ishida Y., Kuo F., Stanger B.Z., and Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8 (1998) 297-303
27. Liu Z.G., Hsu H., Goeddel D.V., and Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87 (1996) 565-576
28. Falschlehner C., Emmerich C.H., Gerlach B., and Walczak H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 39 (2007) 1462-1475
29. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 (2000) 611-620
30. Lin Y., Devin A., Cook A., et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol. Cell Biol. 20 (2000) 6638-6645
31. Lawrence D., Shahrokh Z., Marsters S., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
32. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7 (2008) 1001-1012
33. Held J., and Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist. Update 4 (2001) 243-252
34. Festjens N., Vanden Berghe T., Cornelis S., and Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 14 (2007) 400-410
35. Stanger B.Z., Leder P., Lee T.H., Kim E., and Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81 (1995) 513-523
36. Bertrand M.J., Milutinovic S., Dickson K.M., et al. CIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell. 30 (2008) 689-700
37. O'Donnell M.A., Legarda-Addison D., Skountzos P., Yeh W.C., and Ting A.T. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr. Biol. 17 (2007) 418-424
38. Lewis J., Devin A., Miller A., et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J. Biol. Chem. 275 (2000) 10519-10526
39. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7 (1997) 821-830
40. Muhlenbeck F., Haas E., Schwenzer R., et al. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J. Biol. Chem. 273 (1998) 33091-33098
41. Wang P., Zhang J., Bellail A., et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 19 (2007) 2237-2246
42. Yu L., Alva A., Su H., et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304 (2004) 1500-1502